2 min read
1 min read
Learn how our strategic and regulatory team was able to work with a biopharmaceutical sponsor to advance oncology innovation through adaptive trial design. Our collaborative efforts led to successful execution of a multi-regional Phase 3 study with balanced global enrollment and preserved data integrity in an open-label design.
A biopharmaceutical company developing therapies for solid tumor cancers partnered with Veristat’s strategic and regulatory experts to design and support a Phase 3, open-label, randomized, multi-regional clinical trial that was aligned with the latest FDA guidance. The sponsor sought to compare a novel therapy to standard of care while ensuring broad geographic representation to support future regulatory applications in the US, EU, and Asia.
In this case study, learn how our team was able to work with our sponsor to solve challenges across:
-
Geographic enrollment planning
-
Regional enrollment monitoring
-
Open-label design bias mitigation
-
Data integrity preservation
-
Diversity target optimization
-
Statistical analysis planning
Download our complete case study "Advancing Oncology Innovation with Adaptive Trial Designs"
